Sunday 06 Apr, 2025 04:27 AM
Site map | Locate Us | Login
   Bajel Projects appoints Nitesh Bhandari as CFO & Joint President    Lemon Tree Hotels signs a new property in Uttar Pradesh    AstraZeneca Pharma gets CDSCO nod to import and distribute TAGRISSO (Osimertinib)    CARE Ratings upgrades LT rating of Elpro International to 'A-' with 'stable' outlook    CARE Ratings reaffirms Trident' LT rating at 'AA'; maintains 'stable' outlook    Godrej Properties to develop premium residential project in Versova    Narayana Hrudayalaya inks O&M pact with Kammavari Sangham for 110-bed hospital    Indian Bank's total deposits climb 7% YoY to Rs 7.37 lakh crore in Q4    Force Motors' domestic sales climb 11% YoY in March 2025    IndusInd Bank's total deposits rises 7% YoY in Q4    Ujjivan SFB rises after total deposits climb 20% YoY in Q4    Market tumble for 2nd day amid trump tariffs decision; border mkt underperforms    HUDCO board OKs to raise upto Rs 65,000 crore in FY26    DMart revenue jumps 17% YoY in Q4 FY25    Garware Hi Tech Films Ltd leads losers in 'A' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
AstraZeneca Pharma gets CDSCO nod to import and distribute TAGRISSO (Osimertinib)
05-Apr-25   14:43 Hrs IST

The newly approved indication allows Osimertinib to be used in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

The company said that this approval paves the way for the marketing of Osimertinib Tablets 40 mg and 80 mg (TAGRISSO) in India for the specified additional indication, subject to the receipt of any related statutory approvals.

AstraZeneca Pharma India is engaged in the business of manufacture, distribution, and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company.

The company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24. Revenue from operations jumped 44% to Rs 440.29 crore in Q3 FY25 as compared with Rs 305.79 crore in Q3 FY24.

The scrip fell 2.27% to end at Rs 7,908.50 on Friday, 4 April 2025.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking Hit Count : 40005212
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd